Sponsors (6)
The bill increases early, detailed visibility into drug supply chains—helping patients, clinicians, and regulators prevent or mitigate shortages—at the cost of higher compliance burdens, potential commercial confidentiality and security risks, and possible gaps for biologic products.
Patients (especially those on life‑supporting or chronic therapies), hospitals, and clinicians will receive earlier and more frequent alerts about impending or sudden drug supply disruptions (including 10‑business‑day notices for sudden changes and twice‑yearly reports), giving time to secure alternatives and adjust treatments.
FDA and other regulators will get more actionable supply‑chain details (API sources, supplier identities, production quantities, alternative sources, device issues), improving oversight, inspection targeting, contamination/quality response, and planning for mitigation.
Hospitals, pharmacies, and health systems gain greater supply‑chain transparency that can enable proactive sourcing and diversification to reduce economic disruption from shortages and lower downstream costs from shortage‑related care delays.
Manufacturers and suppliers will face higher compliance and reporting costs (detailed twice‑yearly disclosures and accelerated notification timelines), which could raise drug prices or reduce incentives to produce low‑margin medicines.
Manufacturers and suppliers risk exposing proprietary commercial information (supplier identities, API sources, production quantities, alternatives), creating competitive and legal confidentiality concerns.
Patients dependent on biological products (e.g., certain vaccines and monoclonal antibodies), including seniors and immunocompromised people, could face delayed shortage reporting because biologics are excluded by default, reducing early warning for those supplies.
Based on analysis of 3 sections of legislative text.
Tightens FDA drug-shortage notification rules, excludes most biologics by default, and requires twice-yearly API/supplier reporting with supplier names and volume data.
Official title: Amend the Federal Food, Drug, and Cosmetic Act to provide for notification by manufacturers of critical drugs of increased demand, and for other purposes.
Introduced August 1, 2025 by Amy Klobuchar · Last progress August 1, 2025
Changes to FDA law require drug makers to give faster, fuller notice when they stop or interrupt production of drugs or active ingredients and to provide regular, detailed supplier information to FDA. The bill narrows the statutory definition of covered drugs to exclude biological products unless FDA later includes them by rule, and it directs FDA to share information about supply disruptions for covered drugs. Manufacturers must notify FDA sooner for certain interruptions (within 10 business days), keep the existing 6-month prior-notice requirement where applicable, and include specific details (API sources, expected duration, device contributions, alternatives). Registrants must also submit twice-yearly reports listing API and intermediate suppliers and volumes used, and may provide updates at other times.